The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...

Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therapeutics.

Workers labour on a steel frame at a construction site in central Seoul, South Korea, March 25, 2016. REUTERS/Kim Hong-Ji/File Photo South Korea's factory activity contracted in December, with ...